trans-3-Indoleacrylic acid
Based on 1 publication(s) in Google Scholar
Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 29953-71-7
- Formula: C11H9NO2
- Molecular Weight:187.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) trans-3-Indoleacrylic acid
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Microbial Metabolite |
Trans-3-Indoleacrylic acid activites AHR for increased expression of ALDH1A3, which generates NADH for FSP1-mediated synthesis of coenzyme Q10[1].
Trans-3-Indoleacrylic acid inhibits RSL3 induced ferroptosis in cells HT1080 and 786-O, (50 μM, 24 h),
decreases lipids peroxidation (50 μM, 4 h)[1].
Trans-3-Indoleacrylic acid inhibits IKE-induced (10 μM) ferroptosis in HT29 tumor spheroids (100 μM, 48 h ) and HT29 organoids (100 μM, 72 h ) and promotes tumor growth[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT29, HT1080
-
Concentration:5-500 μM
-
Incubation Time:24 h
-
Result:Inhibited ferroptosis in HT29 and HT1080, with presence of AHR or FSP1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HT29 tumor-bearing xenograft nu/nu mice[1]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection, three times a week
-
Result:Promoted tumor growth with deficiency of AHR or FSP1.
Chemical Information
-
CAS No. 29953-71-7
-
Appearance Solid
-
Molecular Weight 187.19
-
Formula C11H9NO2
-
Color White to off-white
-
SMILES
O=C(/C=C/C1=CNC2=C1C=CC=C2)O.[E]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of Guben Xiezhuo decoction against renal fibrosis. [Abstract]2025 Aug 20;15(1):30479. PMID: 40830226
Solvent & Solubility
DMSO : 250 mg/mL (1335.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (11.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.3422 mL | 26.7108 mL | 53.4217 mL | 133.5541 mL |
| 5 mM | 1.0684 mL | 5.3422 mL | 10.6843 mL | 26.7108 mL | |
| 10 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL | 13.3554 mL | |
| 15 mM | 0.3561 mL | 1.7807 mL | 3.5614 mL | 8.9036 mL | |
| 20 mM | 0.2671 mL | 1.3355 mL | 2.6711 mL | 6.6777 mL | |
| 25 mM | 0.2137 mL | 1.0684 mL | 2.1369 mL | 5.3422 mL | |
| 30 mM | 0.1781 mL | 0.8904 mL | 1.7807 mL | 4.4518 mL | |
| 40 mM | 0.1336 mL | 0.6678 mL | 1.3355 mL | 3.3389 mL | |
| 50 mM | 0.1068 mL | 0.5342 mL | 1.0684 mL | 2.6711 mL | |
| 60 mM | 0.0890 mL | 0.4452 mL | 0.8904 mL | 2.2259 mL | |
| 80 mM | 0.0668 mL | 0.3339 mL | 0.6678 mL | 1.6694 mL | |
| 100 mM | 0.0534 mL | 0.2671 mL | 0.5342 mL | 1.3355 mL |